<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02054754</url>
  </required_header>
  <id_info>
    <org_study_id>ETS2101-101</org_study_id>
    <nct_id>NCT02054754</nct_id>
  </id_info>
  <brief_title>Assessment of Single Doses of Oral Dexanabinol in Healthy Subjects</brief_title>
  <official_title>Assessment of Safety, Tolerability and Pharmacokinetics of Single Doses of Oral Dexanabinol in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>e-Therapeutics PLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>e-Therapeutics PLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety and observe the pharmacokinetics
      (distribution and elimination of the drug) of the compound dexanabinol (ETS2101) in healthy
      male subjects following a single oral dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability Based on the Number of Participants With Adverse Events and Comparison of Baseline and Post Dose Parameters</measure>
    <time_frame>Participants will be followed until follow up visit, 6-11 days after dosing</time_frame>
    <description>Safety and tolerability based on the number of participants with adverse events. Assessment and comparison to baseline of the following:
Physical exam
Safety bloods and urinalysis
12-lead ECG
Vital signs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve of the Compound Dexanabinol (ETS2101) From Pre-dose up to 48 Hours Post Dose</measure>
    <time_frame>Pre-dose, 0.5,1,1.5,2,3,4,5,6,8,10,12,16,24,36,48 hours post dose</time_frame>
    <description>Pharmacokinetic parameters will be assessed in a blinded fashion at the end of each cohort, prior to dose escalation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacodynamic Biomarker Assessment</measure>
    <time_frame>Pre-dose, 1, 6 and 24 hours post dose</time_frame>
    <description>Blood samples taken and analysed for the purposes of the identification and quantification of pharmacodynamic biomarkers pre-dose and at several points after dosing.</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Safety</condition>
  <condition>Tolerability</condition>
  <condition>Pharmacokinetics</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Dexanabinol Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of dexanabinol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexanabinol Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of dexanabinol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexanabinol Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of dexanabinol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexanabinol Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of dexanabinol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexanabinol Dose Level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of dexanabinol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single oral dose of matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexanabinol Dose Level 1</intervention_name>
    <description>Oral formulation of dexanabinol</description>
    <arm_group_label>Dexanabinol Dose Level 1</arm_group_label>
    <other_name>ETS2101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexanabinol Dose Level 2</intervention_name>
    <description>Oral formulation of dexanabinol</description>
    <arm_group_label>Dexanabinol Dose Level 2</arm_group_label>
    <other_name>ETS2101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexanabinol Dose Level 3</intervention_name>
    <description>Oral formulation of dexanabinol</description>
    <arm_group_label>Dexanabinol Dose Level 3</arm_group_label>
    <other_name>ETS2101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexanabinol Dose Level 4</intervention_name>
    <description>Oral formulation of dexanabinol</description>
    <arm_group_label>Dexanabinol Dose Level 4</arm_group_label>
    <other_name>ETS2101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexanabinol Dose Level 5</intervention_name>
    <description>Oral formulation of dexanabinol</description>
    <arm_group_label>Dexanabinol Dose Level 5</arm_group_label>
    <other_name>ETS2101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males aged 18 to 45 years

          -  Body mass index 18.0 to 32.0 kg/m2, or if outside the range, considered not clinically
             significant by the investigator

        Exclusion Criteria:

          -  Participation in a clinical research study within the previous 3 months

          -  Current smokers and those who have smoked within the last 12 months

          -  History of any drug or alcohol abuse in the past 2 years
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Evans, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Clinical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Clinical</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2013</study_first_submitted>
  <study_first_submitted_qc>February 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2014</study_first_posted>
  <results_first_submitted>January 25, 2016</results_first_submitted>
  <results_first_submitted_qc>May 17, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 23, 2016</results_first_posted>
  <last_update_submitted>May 17, 2016</last_update_submitted>
  <last_update_submitted_qc>May 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dexanabinol</keyword>
  <keyword>Oral</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HU 211</mesh_term>
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dexanabinol Dose Level 1</title>
          <description>Single oral dose of dexanabinol at Dose Level 1
Dexanabinol: Oral formulation of dexanabinol</description>
        </group>
        <group group_id="P2">
          <title>Dexanabinol Dose Level 2</title>
          <description>Single oral dose of dexanabinol at Dose level 2
Dexanabinol: Oral formulation of dexanabinol</description>
        </group>
        <group group_id="P3">
          <title>Dexanabinol Dose Level 3</title>
          <description>Single oral dose of dexanabinol at Dose level 3
Dexanabinol: Oral formulation of dexanabinol</description>
        </group>
        <group group_id="P4">
          <title>Dexanabinol Dose Level 4</title>
          <description>Single oral dose of dexanabinol at Dose level 4
Dexanabinol: Oral formulation of dexanabinol</description>
        </group>
        <group group_id="P5">
          <title>Dexanabinol Dose Level 5</title>
          <description>Single oral dose of dexanabinol at Dose level 5
Dexanabinol: Oral formulation of dexanabinol</description>
        </group>
        <group group_id="P6">
          <title>Placebo</title>
          <description>Single oral dose of matching placebo
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Healthy male subjects between 18 and 45 years of age with a body mass index between 18.0 and 32.0 kg/m2 or, if outside the range, considered not clinically significant by the investigator.</population>
      <group_list>
        <group group_id="B1">
          <title>Dexanabinol</title>
          <description>Single oral dose of dexanabinol
Dexanabinol: Oral formulation of dexanabinol</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Single oral dose of matching placebo
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.8" spread="8.5"/>
                    <measurement group_id="B2" value="28.1" spread="8.3"/>
                    <measurement group_id="B3" value="31.1" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability Based on the Number of Participants With Adverse Events and Comparison of Baseline and Post Dose Parameters</title>
        <description>Safety and tolerability based on the number of participants with adverse events. Assessment and comparison to baseline of the following:
Physical exam
Safety bloods and urinalysis
12-lead ECG
Vital signs</description>
        <time_frame>Participants will be followed until follow up visit, 6-11 days after dosing</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexanabinol</title>
            <description>Single oral dose of dexanabinol
Dexanabinol: Oral formulation of dexanabinol</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Single oral dose of matching placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability Based on the Number of Participants With Adverse Events and Comparison of Baseline and Post Dose Parameters</title>
          <description>Safety and tolerability based on the number of participants with adverse events. Assessment and comparison to baseline of the following:
Physical exam
Safety bloods and urinalysis
12-lead ECG
Vital signs</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve of the Compound Dexanabinol (ETS2101) From Pre-dose up to 48 Hours Post Dose</title>
        <description>Pharmacokinetic parameters will be assessed in a blinded fashion at the end of each cohort, prior to dose escalation.</description>
        <time_frame>Pre-dose, 0.5,1,1.5,2,3,4,5,6,8,10,12,16,24,36,48 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexanabinol Dose Level 1</title>
          </group>
          <group group_id="O2">
            <title>Dose Level 2</title>
          </group>
          <group group_id="O3">
            <title>Dose Level 3</title>
          </group>
          <group group_id="O4">
            <title>Dose Level 4</title>
          </group>
          <group group_id="O5">
            <title>Dose Level 5</title>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve of the Compound Dexanabinol (ETS2101) From Pre-dose up to 48 Hours Post Dose</title>
          <description>Pharmacokinetic parameters will be assessed in a blinded fashion at the end of each cohort, prior to dose escalation.</description>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" spread="0"/>
                    <measurement group_id="O2" value="61.3" spread="75.7"/>
                    <measurement group_id="O3" value="109" spread="102.7"/>
                    <measurement group_id="O4" value="226" spread="50.7"/>
                    <measurement group_id="O5" value="192" spread="68.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pharmacodynamic Biomarker Assessment</title>
        <description>Blood samples taken and analysed for the purposes of the identification and quantification of pharmacodynamic biomarkers pre-dose and at several points after dosing.</description>
        <time_frame>Pre-dose, 1, 6 and 24 hours post dose</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dexanabinol Dose Level 1</title>
          <description>Single oral dose of dexanabinol
Dexanabinol: Oral formulation of dexanabinol</description>
        </group>
        <group group_id="E2">
          <title>Dexanabinol Dose Level 2</title>
          <description>Single oral dose of dexanabinol
Dexanabinol: Oral formulation of dexanabinol</description>
        </group>
        <group group_id="E3">
          <title>Dexanabinol Dose Level 3</title>
          <description>Single oral dose of dexanabinol
Dexanabinol: Oral formuulation of dexanabinol</description>
        </group>
        <group group_id="E4">
          <title>Dexanabinol Dose Level 4</title>
          <description>Single oral dose of dexanabinol
Dexanabinol: Oral formulation of dexanabinol</description>
        </group>
        <group group_id="E5">
          <title>Dexanabinol Dose Level 5</title>
          <description>Single oral dose of dexanabinol
Dexanabinol: Oral formulation of dexanabinol</description>
        </group>
        <group group_id="E6">
          <title>Placebo</title>
          <description>Single oral dose of matching placebo
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Acute otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Musculo-skeletal stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Operations Manager</name_or_title>
      <organization>e-Therapeutics Plc</organization>
      <phone>+44 1993 880000</phone>
      <email>contact@etherapeutics.co.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

